Cargando…

The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure

BACKGROUND AND OBJECTIVES: Dysfunction of arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) contributes significantly to morbidity and hospitalization in the dialysis population. We evaluated the primary patency of AVFs following percutaneous transluminal angioplasty (PTA) in haemodialys...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Woo Shin, Pyun, Wook Bum, Kang, Byung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193042/
https://www.ncbi.nlm.nih.gov/pubmed/22022326
http://dx.doi.org/10.4070/kcj.2011.41.9.512
_version_ 1782213830553632768
author Kim, Woo Shin
Pyun, Wook Bum
Kang, Byung Chul
author_facet Kim, Woo Shin
Pyun, Wook Bum
Kang, Byung Chul
author_sort Kim, Woo Shin
collection PubMed
description BACKGROUND AND OBJECTIVES: Dysfunction of arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) contributes significantly to morbidity and hospitalization in the dialysis population. We evaluated the primary patency of AVFs following percutaneous transluminal angioplasty (PTA) in haemodialysis patients. SUBJECTS AND METHODS: We performed 231 interventions in 118 patients with a mean age of 62.1±12.9 years. We performed 122 interventions in 53 AVG patients (44.9%), and 109 interventions in 65 AVF patients (55.1%). If there was thrombosis of the vascular access, urokinase was administered and/or thrombus aspiration was performed. The stent was inserted when balloon dilatation did not expand sufficiently or elastic recoil occurred. RESULTS: For the 118 patients, the median patency time was 10.45±10.29 months at 92 months of follow-up. The primary patencies for stenotic AVFs at 6, 12, 24, 36, 48, and 60 months were 63.4%, 41.4%, 17.0%, 9.7%, 7.3%, and 2.4%, respectively. The primary patencies for AVGs at 6, 12, 24, and 36 months were 36.9%, 19.5%, 10.8%, 2.1%, respectively, and were obtained by means of the Kaplan-Meier analysis (log rank=6.42, p<0.05). The median patency time was 11.0 months and 4.45 months in the non-thrombus and thrombus groups, respectively. The complication rate was 1.73% (4/231); two cases of pseudoaneurysms and two cases of extravasation were detected. All therapy failures (5/231) occurred in thrombotic lesions of AVGs and were treated surgically. CONCLUSION: PTA is an efficacious method for the correction of stenosis of AVFs for hemodialysis, thus prolonging the patency of the fistulas.
format Online
Article
Text
id pubmed-3193042
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Korean Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-31930422011-10-21 The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure Kim, Woo Shin Pyun, Wook Bum Kang, Byung Chul Korean Circ J Original Article BACKGROUND AND OBJECTIVES: Dysfunction of arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) contributes significantly to morbidity and hospitalization in the dialysis population. We evaluated the primary patency of AVFs following percutaneous transluminal angioplasty (PTA) in haemodialysis patients. SUBJECTS AND METHODS: We performed 231 interventions in 118 patients with a mean age of 62.1±12.9 years. We performed 122 interventions in 53 AVG patients (44.9%), and 109 interventions in 65 AVF patients (55.1%). If there was thrombosis of the vascular access, urokinase was administered and/or thrombus aspiration was performed. The stent was inserted when balloon dilatation did not expand sufficiently or elastic recoil occurred. RESULTS: For the 118 patients, the median patency time was 10.45±10.29 months at 92 months of follow-up. The primary patencies for stenotic AVFs at 6, 12, 24, 36, 48, and 60 months were 63.4%, 41.4%, 17.0%, 9.7%, 7.3%, and 2.4%, respectively. The primary patencies for AVGs at 6, 12, 24, and 36 months were 36.9%, 19.5%, 10.8%, 2.1%, respectively, and were obtained by means of the Kaplan-Meier analysis (log rank=6.42, p<0.05). The median patency time was 11.0 months and 4.45 months in the non-thrombus and thrombus groups, respectively. The complication rate was 1.73% (4/231); two cases of pseudoaneurysms and two cases of extravasation were detected. All therapy failures (5/231) occurred in thrombotic lesions of AVGs and were treated surgically. CONCLUSION: PTA is an efficacious method for the correction of stenosis of AVFs for hemodialysis, thus prolonging the patency of the fistulas. The Korean Society of Cardiology 2011-09 2011-09-29 /pmc/articles/PMC3193042/ /pubmed/22022326 http://dx.doi.org/10.4070/kcj.2011.41.9.512 Text en Copyright © 2011 The Korean Society of Cardiology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Woo Shin
Pyun, Wook Bum
Kang, Byung Chul
The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure
title The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure
title_full The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure
title_fullStr The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure
title_full_unstemmed The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure
title_short The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure
title_sort primary patency of percutaneous transluminal angioplasty in hemodialysis patients with vascular access failure
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193042/
https://www.ncbi.nlm.nih.gov/pubmed/22022326
http://dx.doi.org/10.4070/kcj.2011.41.9.512
work_keys_str_mv AT kimwooshin theprimarypatencyofpercutaneoustransluminalangioplastyinhemodialysispatientswithvascularaccessfailure
AT pyunwookbum theprimarypatencyofpercutaneoustransluminalangioplastyinhemodialysispatientswithvascularaccessfailure
AT kangbyungchul theprimarypatencyofpercutaneoustransluminalangioplastyinhemodialysispatientswithvascularaccessfailure
AT kimwooshin primarypatencyofpercutaneoustransluminalangioplastyinhemodialysispatientswithvascularaccessfailure
AT pyunwookbum primarypatencyofpercutaneoustransluminalangioplastyinhemodialysispatientswithvascularaccessfailure
AT kangbyungchul primarypatencyofpercutaneoustransluminalangioplastyinhemodialysispatientswithvascularaccessfailure